Sector Focus


Caliber has successfully planned with both venture backed private development stage companies and publicly traded biopharmaceutical companies. We understand the unique challenges of emerging companies as well as global biotech organizations and we have developed a keen sense of what it takes to discover and develop biologically derived treatments to enhance the quality of care in markets with substantially under met medical needs.



At Trevena, our mission is to deliver innovative solutions to patients and healthcare providers confronting serious medical conditions. Our lead product candidate is OLINVO (oliceridine injection), an innovative new chemical entity that has recently completed Phase 3 pivotal efficacy studies for the management of moderate-to-severe acute pain. OLINVO is designated a Breakthrough Therapy by the U.S. Food and Drug Administration. We also have discovered several other product candidates with the potential to address problems across a wide range of therapeutic areas, including moderate-to-severe acute and chronic pain, and acute episodic migraine. In addition, we have an early-stage portfolio of drug discovery programs currently in lead optimization.

Search Projects